Scientists May Finally Understand How The World’s Most Common Diabetes Drug Works

Metformin’s Real Secret May Be in Your Gut, Not Your Liver

For decades, metformin has been the go-to pill for managing type 2 diabetes, prescribed widely around the world. Now, a new study from researchers at Northwestern University Feinberg School of Medicine suggests the answer to why it works may have been hiding in the lining of the small intestine.

Research published in Nature Metabolism finds that metformin’s blood-sugar-lowering effects may depend far more on the gut than scientists once appreciated, rather than acting mainly through the liver alone. Specifically, the drug appears to work by blocking a key piece of cellular machinery in intestinal cells, forcing the gut to act like a sponge that soaks up excess sugar from the bloodstream. That finding reshapes more than 30 years of scientific thinking about one of the most-used medications on the planet.

It also reaches beyond metformin itself. The same gut-based mechanism appears to drive the blood-sugar-lowering effects of two other compounds: phenformin, a related drug pulled from the market due to safety concerns decades ago, and berberine, a plant-derived supplement sold over the counter. All three, despite their different origins, appear to work through the same fundamental switch inside intestinal cells.

How Metformin Actually Lowers Blood Sugar

To understand what the researchers found, it helps to know how cells make energy. Deep inside nearly every cell, structures called mitochondria act like tiny power plants, using a chain of molecular machines to convert food into usable energy. The first of these machines, called complex I, is essentially the on-switch for the whole process.

Metformin jams that switch in intestinal cells. When complex I is blocked, cells can’t run their normal energy-making process. Instead, they’re forced into an alternative route that burns through glucose rapidly and produces lactate as a byproduct. The intestines get pressed into consuming excess sugar, pulling it out of circulation and keeping blood sugar down.

This also explains something that has puzzled cancer doctors for years. A scan called FDG-PET, widely used for tumor detection, tracks which tissues are consuming sugar fastest. Patients taking metformin lit up in their intestines during these scans badly enough that stopping the drug before imaging became standard practice by the early 2010s. This research reveals why: metformin was turning the intestines into a sugar-hungry organ.

Mice With a Built-In Override

At the heart of the study was a genetic approach using male mice. Researchers engineered a mouse model in which intestinal cells were given a special protein, borrowed from baker’s yeast, that bypasses the energy-making switch metformin blocks. In these modified mice, intestinal cells could keep making energy normally even with metformin present.

Normal mice receiving metformin showed blood sugar drops during glucose tolerance tests, a standard measure of how the body handles a sugar load. In mice with the bypass, metformin largely failed to do its job: no extra glucose uptake in the gut, no increase in lactate, and no meaningful blood sugar reduction.

One unexpected finding involved timing. In these mouse experiments, the glucose-lowering benefit appeared to depend on repeated dose-by-dose exposure in the gut, not a lasting change after the drug cleared. When metformin was delivered through drinking water over an extended period, it failed to improve blood sugar control regardless of whether mice had the intestinal bypass. Each dose hitting the intestine acutely appears to be the key event.

Berberine: The Supplement That Works the Same Way

Perhaps the most practical part of the study involves berberine, a yellow plant compound used in traditional medicine for centuries and now widely sold in health food stores. Studies have suggested it works for blood sugar, but the mechanism was murky, partly because berberine is poorly absorbed from the gut into the bloodstream.

That poor absorption, the researchers argue, turns out to be a feature rather than a bug. Berberine stays concentrated in the intestinal lining, exactly where it needs to be to block the energy switch. When researchers paired a low dose of berberine with encequidar, a drug that changes how the gut handles berberine, berberine’s glucose-lowering effect appeared in normal mice. That effect disappeared in mice whose intestinal cells carried the bypass, a cleaner result even than what was seen with metformin, suggesting the gut is essentially the only place berberine acts.

Berberine is classified as a stronger inhibitor of that cellular energy switch than either metformin or phenformin at the molecular level, according to measurements cited in the paper. Even so, the study was conducted primarily in male mice, not in human clinical trials, and was not designed to test whether berberine should replace prescribed diabetes medication.

Metformin has been prescribed for type 2 diabetes for generations, and it works. Knowing how it works opens the door to designing better versions, or entirely new drugs, that target the gut’s energy machinery more precisely. For patients already taking it every day, the most important action has apparently been happening quietly in the gut all along.

---

Disclaimer: This article is based on a single peer-reviewed study conducted primarily in male mice. Findings have not been confirmed in large-scale human clinical trials. Nothing in this article should be taken as medical advice. Consult a qualified healthcare provider before making any changes to diabetes medication or supplement use.

---